U.K. trial hold for Sarepta's SRP-4045 combo

Sarepta Therapeutics Inc. (NASDAQ:SRPT) said it halted dosing at U.K. study sites in the Phase III ESSENCE trial evaluating golodirsen (SRP-4053) and casimersen (SRP-4045) to treat Duchenne muscular dystrophy.

In a statement, the company said the stoppage resulted from a serious adverse event "that could possibly be related to the investigational drug product." Sarepta did not respond to a query regarding which candidate may be tied to the event. It noted that the SAE, rhabdomyolysis, is not unusual to observe in DMD patients...